
Pa



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplu.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/755,190

01/09/2004

Karoly Nikolics

P0576P1C3

09157 GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080 CONFIRMATION NO. 9193
FORMALITIES LETTER
OC000000013812651

Date Mailed: 09/16/2004


NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

An application number and filing date have been accorded to this application. The application is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

• A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, is required. The specification, claims, or abstract page(s) submitted is not acceptable and cannot be scanned or properly stored because:



• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

OCT 2 7 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Karoly Nikolics et al.

Serial No.: 10/755,190

Filed: January 9, 2004

For:

GLYCOPROTEIN HORMONE

RECEPTOR MOLECULES

Group Art Unit: 1632

Examiner: To Be Assigned

Confirmation No: 9193

Customer No: 09157

EXPRESS MAIL LABEL NO.: EV 385 660 013 US

DATE OF DEPOSIT: OCTOBER 27, 2004

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS - FILING DATE GRANTED

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is responsive to the Notice to File Corrected Application Papers - Filing Date Granted mailed by the U.S. Patent Office on September 16, 2004. Transmitted herewith are the following documents:

- 1. Copy of Notice to File Corrected Application Papers;
- 2. Substitute Specification;
- 3. Statement Under 37 C.F.R. §1.125(b);
- 4. Sequence Listing, in paper copy and a computer readable diskette;
- 5. Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f) and (g); and
- 6. Postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: October 27, 2004

Steven X. Cui, Ph.D.

Reg. No. 44,637

Telephone No. (650) 225-8674





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Group Art Unit: 1632

Karoly Nikolics et al. Examiner: To Be Assigned

Serial No.: 10/755,190 | Confirmation No: 9193

Filed: January 9, 2004 Customer No: 09157

Title: GLYCOPROTEIN HORMONE RECEPTOR MOLECULES EXPRESS MAIL LABEL NO.: EV 385 660 013 US

DATE OF DEPOSIT: OCTOBER 27, 2004

STATEMENT UNDER 37 C.F.R. §1.125(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby state, as required by 37 C.F.R. §1.125(b), that the accompanying substitute specification includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: October 27, 2004

Steven X. Cui, Ph.D.

Reg. No. 44,637

Telephone No. (650) 225-8674